NOTCH1 and acute lymphoblastic leukemia: Despite its critical role in T-ALL, NOTCH1-targeting therapies have failed so far to produce strong anti-tumor responses, largely due to difficulties in finding acceptable therapeutic windows for these agents (Takebe et al., 2014; Wei et al., 2010).